Compare VOR & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOR | INMD |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.7M | 842.0M |
| IPO Year | 2021 | 2018 |
| Metric | VOR | INMD |
|---|---|---|
| Price | $14.67 | $13.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 5 |
| Target Price | ★ $45.33 | $17.33 |
| AVG Volume (30 Days) | ★ 892.8K | 728.9K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $12.72 |
| 52 Week High | $49.95 | $16.74 |
| Indicator | VOR | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.02 | 47.15 |
| Support Level | $11.74 | $13.30 |
| Resistance Level | $14.73 | $14.70 |
| Average True Range (ATR) | 0.97 | 0.31 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 21.21 | 52.78 |
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.